{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:58:55Z","timestamp":1777593535708,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,16]],"date-time":"2022-10-16T00:00:00Z","timestamp":1665878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN 159925"],"award-info":[{"award-number":["FRN 159925"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["9566282"],"award-info":[{"award-number":["9566282"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.drudis.2022.103407","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T06:02:02Z","timestamp":1665640922000},"page":"103407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evidence-based support for phenotypic drug discovery in acute myeloid leukemia"],"prefix":"10.1016","volume":"27","author":[{"given":"Sean","family":"Vandersluis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickie","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.103407_b0005","unstructured":"FDA. Guidance for Industry: Applications Covered by Section 505(b)(2). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/applications-covered-section-505b2. Published December, 1999. Accessed 11 June, 2022."},{"key":"10.1016\/j.drudis.2022.103407_b0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.drudis.2022.103407_b0015","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd4366","article-title":"Phenotypic screening in cancer drug discovery-past, present and future","volume":"13","author":"Moffat","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.103407_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.103407_b0025","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2022.103407_b0030","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra061808","article-title":"Cancer stem cells","volume":"355","author":"Jordan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2022.103407_b0035","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","article-title":"Genetic and epigenetic heterogeneity in acute myeloid leukemia","volume":"36","author":"Li","year":"2016","journal-title":"Curr Opin Genet Dev"},{"key":"10.1016\/j.drudis.2022.103407_b0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.103407_b0045","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.103407_b0050","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.103407_b0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.drudis.2022.103407_b0060","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/jcp.29044","article-title":"Cancer stem cells: a review from origin to therapeutic implications","volume":"235","author":"Atashzar","year":"2020","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.drudis.2022.103407_b0065","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ccell.2018.08.007","article-title":"Identification of chemotherapy-induced leukemic-regenerating cells reveals a transient vulnerability of human AML recurrence","volume":"34","author":"Boyd","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2022.103407_b0070","doi-asserted-by":"crossref","first-page":"659253","DOI":"10.3389\/fonc.2021.659253","article-title":"Escape From treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"11","author":"van Gils","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2022.103407_b0075","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrc.2016.3","article-title":"Leukaemia, \u201cfirsts\u201d in cancer research and treatment","volume":"16","author":"Greaves","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2022.103407_b0080","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.103407_b0085","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2022.103407_b0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/13543784.2013.739605","article-title":"Discontinued drugs in 2012: oncology drugs","volume":"22","author":"Williams","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.drudis.2022.103407_b0095","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/ijc.2910430519","article-title":"A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity","volume":"43","author":"Meyer","year":"1989","journal-title":"Int J Cancer"},{"key":"10.1016\/j.drudis.2022.103407_b0100","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2022.103407_b0105","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2022.103407_b0110","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11912-021-01108-9","article-title":"3+7 Combined chemotherapy for acute myeloid leukemia: is it time to say goodbye?","volume":"23","author":"Tang","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.drudis.2022.103407_b0115","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/ncb3625","article-title":"Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche","volume":"19","author":"Boyd","year":"2017","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.drudis.2022.103407_b0120","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2012.03.049","article-title":"Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells","volume":"149","author":"Sachlos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.103407_b0125","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1182\/bloodadvances.2018015677","article-title":"A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia","volume":"2","author":"Aslostovar","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2022.103407_b0130","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1002\/anie.201208749","article-title":"Target identification for small bioactive molecules: finding the needle in the haystack","volume":"52","author":"Ziegler","year":"2013","journal-title":"Angew Chemie Int Ed Eng"},{"key":"10.1016\/j.drudis.2022.103407_b0135","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.chembiol.2021.01.010","article-title":"The future of phenotypic drug discovery","volume":"28","author":"Berg","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2022.103407_b0140","article-title":"Mediators of hedgehog signaling pathways, compositions, and uses related thereto","author":"Rubin","year":"2003","journal-title":"PCT Int Pat Appl Publ WO 2003011219"},{"key":"10.1016\/j.drudis.2022.103407_b0145","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd2311","article-title":"Universal strategies in research and drug discovery based on protein-fragment complementation assays","volume":"6","author":"Michnick","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.103407_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1021\/ml2002423","article-title":"Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened","volume":"3","author":"Munchhof","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2022.103407_b0155","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrd.2017.111","article-title":"Opportunities and challenges in phenotypic drug discovery: an industry perspective","volume":"16","author":"Moffat","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.103407_b0160","doi-asserted-by":"crossref","first-page":"293ps15","DOI":"10.1126\/scitranslmed.aab1201","article-title":"Developing predictive assays: the phenotypic screening \u201crule of 3\u201d","volume":"7","author":"Vincent","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.103407_b0165","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/leu.2011.238","article-title":"The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations","volume":"26","author":"Tiacci","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2022.103407_b0170","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1172\/JCI93041","article-title":"Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies","volume":"127","author":"Cole","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2022.103407_b0175","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41408-018-0072-9","article-title":"DNMT3AR882-associated hypomethylation patterns are maintained in primary AML xenografts, but not in the DNMT3AR882C OCI-AML3 leukemia cell line","volume":"8","author":"Chen","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.drudis.2022.103407_b0180","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.chembiol.2017.06.003","article-title":"Mechanisms of skin toxicity associated with metabotropic Glutamate Receptor 5 negative allosteric modulators","volume":"24","author":"Shah","year":"2017","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2022.103407_b0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.drudis.2022.103407_b0190","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.103407_b0195","doi-asserted-by":"crossref","first-page":"eaaw8412","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.drudis.2022.103407_b0200","doi-asserted-by":"crossref","first-page":"10787","DOI":"10.1038\/s41598-020-67846-1","article-title":"Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets in oncology","volume":"10","author":"Bazaga","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2022.103407_b0205","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","article-title":"Synthetic lethality as an engine for cancer drug target discovery","volume":"19","author":"Huang","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2022.103407_b0210","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.drudis.2018.10.009","article-title":"The power of combining phenotypic and target-focused drug discovery","volume":"24","author":"Heilker","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.103407_b0215","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","article-title":"Machine learning identifies stemness features associated with oncogenic dedifferentiation","volume":"173","author":"Malta","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.103407_b0220","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12967-020-02677-2","article-title":"Patient-derived organoid (PDO) platforms to facilitate clinical decision making","volume":"19","author":"Liu","year":"2021","journal-title":"J Transl Med"},{"key":"10.1016\/j.drudis.2022.103407_b0225","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.chembiol.2019.05.007","article-title":"The convergence of stem cell technologies and phenotypic drug discovery","volume":"26","author":"Friese","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2022.103407_b0230","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s42003-019-0305-x","article-title":"A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids","volume":"2","author":"Phan","year":"2019","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2022.103407_b0235","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.chembiol.2019.03.011","article-title":"Phenotypic screening combined with machine learning for efficient identification of breast cancer-selective therapeutic targets","volume":"26","author":"Gautam","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.drudis.2022.103407_b0240","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41467-021-22170-8","article-title":"Drug ranking using machine learning systematically predicts the efficacy of anti-cancer drugs","volume":"12","author":"Gerdes","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2022.103407_b0245","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.drudis.2021.01.013","article-title":"Use of artificial intelligence to enhance phenotypic drug discovery","volume":"26","author":"Malandraki-Miller","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2022.103407_b0250","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.chembiol.2020.08.009","article-title":"Hit triage and validation in phenotypic screening: considerations and strategies","volume":"27","author":"Vincent","year":"2020","journal-title":"Cell Chem Biol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:00:02Z","timestamp":1761224402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622004007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1359644622004007"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103407","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence-based support for phenotypic drug discovery in acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103407"}}